423 related articles for article (PubMed ID: 27340145)
1. Effect of Body Weight on Hemodynamic Response in Patients Receiving Fixed-Dose Vasopressin for Septic Shock.
Hodge EK; Hughes DW; Attridge RL
Ann Pharmacother; 2016 Oct; 50(10):816-23. PubMed ID: 27340145
[TBL] [Abstract][Full Text] [Related]
2. Does body weight impact the efficacy of vasopressin therapy in the management of septic shock?
Miller JT; Welage LS; Kraft MD; Alaniz C
J Crit Care; 2012 Jun; 27(3):289-93. PubMed ID: 21855282
[TBL] [Abstract][Full Text] [Related]
3. Fixed-dose vasopressin compared with titrated dopamine and norepinephrine as initial vasopressor therapy for septic shock.
Hall LG; Oyen LJ; Taner CB; Cullinane DC; Baird TK; Cha SS; Sawyer MD
Pharmacotherapy; 2004 Aug; 24(8):1002-12. PubMed ID: 15338849
[TBL] [Abstract][Full Text] [Related]
4. Impact of Norepinephrine Weight-Based Dosing Compared With Non-Weight-Based Dosing in Achieving Time to Goal Mean Arterial Pressure in Obese Patients With Septic Shock.
Vadiei N; Daley MJ; Murthy MS; Shuman CS
Ann Pharmacother; 2017 Mar; 51(3):194-202. PubMed ID: 27886982
[TBL] [Abstract][Full Text] [Related]
5. Body Mass's Impact on Response to Fixed-Dose Vasopressin in Patients With Septic Shock.
Torbic H; Sacha GL; Bauer SR; Lam SW
Shock; 2018 Oct; 50(4):388-394. PubMed ID: 29240642
[TBL] [Abstract][Full Text] [Related]
6. Effects of continuous vasopressin infusion in patients with septic shock.
Obritsch MD; Jung R; Fish DN; MacLaren R
Ann Pharmacother; 2004; 38(7-8):1117-22. PubMed ID: 15178740
[TBL] [Abstract][Full Text] [Related]
7. Effect of Vasopressin Dose on Hemodynamic Response in Obese Patients With Septic Shock: A Retrospective Observational Study.
Dubrawka CA; Betthauser KD; Pope HE; Gibson GA
Ann Pharmacother; 2021 Dec; 55(12):1447-1454. PubMed ID: 33813908
[TBL] [Abstract][Full Text] [Related]
8. Lack of an effect of body mass on the hemodynamic response to arginine vasopressin during septic shock.
Lam SW; Bauer SR; Cha SS; Oyen LJ
Pharmacotherapy; 2008 May; 28(5):591-9. PubMed ID: 18447658
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Outcomes After Vasopressin Guideline Implementation in Septic Shock.
Wu JY; Stollings JL; Wheeler AP; Semler MW; Rice TW
Ann Pharmacother; 2017 Jan; 51(1):13-20. PubMed ID: 27630192
[TBL] [Abstract][Full Text] [Related]
10. A comparison of initial monotherapy with norepinephrine versus vasopressin for resuscitation in septic shock.
Daley MJ; Lat I; Mieure KD; Jennings HR; Hall JB; Kress JP
Ann Pharmacother; 2013 Mar; 47(3):301-10. PubMed ID: 23447481
[TBL] [Abstract][Full Text] [Related]
11. Evaluating the impact of obesity on safety and efficacy of weight-based norepinephrine dosing in septic shock: A single-center, retrospective study.
Wong PJ; Pandya KA; Flannery AH
Intensive Crit Care Nurs; 2017 Aug; 41():104-108. PubMed ID: 28343834
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of the Early Addition of Vasopressin to Norepinephrine in Septic Shock.
Hammond DA; Cullen J; Painter JT; McCain K; Clem OA; Brotherton AL; Chopra D; Meena N
J Intensive Care Med; 2019; 34(11-12):910-916. PubMed ID: 28820036
[TBL] [Abstract][Full Text] [Related]
13. Prospective Open-label Trial of Early Concomitant Vasopressin and Norepinephrine Therapy versus Initial Norepinephrine Monotherapy in Septic Shock.
Hammond DA; Ficek OA; Painter JT; McCain K; Cullen J; Brotherton AL; Kakkera K; Chopra D; Meena N
Pharmacotherapy; 2018 May; 38(5):531-538. PubMed ID: 29600824
[TBL] [Abstract][Full Text] [Related]
14. Hemodynamic Instability Secondary to Vasopressin Withdrawal in Septic Shock.
Bissell BD; Magee C; Moran P; Bastin MLT; Flannery AH
J Intensive Care Med; 2019 Sep; 34(9):761-765. PubMed ID: 28750598
[TBL] [Abstract][Full Text] [Related]
15. Norepinephrine Dosing in Obese and Nonobese Patients With Septic Shock.
Radosevich JJ; Patanwala AE; Erstad BL
Am J Crit Care; 2016 Jan; 25(1):27-32. PubMed ID: 26724290
[TBL] [Abstract][Full Text] [Related]
16. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study.
Morelli A; Ertmer C; Rehberg S; Lange M; Orecchioni A; Cecchini V; Bachetoni A; D'Alessandro M; Van Aken H; Pietropaoli P; Westphal M
Crit Care; 2009; 13(4):R130. PubMed ID: 19664253
[TBL] [Abstract][Full Text] [Related]
17. Vasopressin versus norepinephrine infusion in patients with septic shock.
Russell JA; Walley KR; Singer J; Gordon AC; Hébert PC; Cooper DJ; Holmes CL; Mehta S; Granton JT; Storms MM; Cook DJ; Presneill JJ; Ayers D;
N Engl J Med; 2008 Feb; 358(9):877-87. PubMed ID: 18305265
[TBL] [Abstract][Full Text] [Related]
18. Hypotension Risk Based on Vasoactive Agent Discontinuation Order in Patients in the Recovery Phase of Septic Shock.
Sacha GL; Lam SW; Duggal A; Torbic H; Reddy AJ; Bauer SR
Pharmacotherapy; 2018 Mar; 38(3):319-326. PubMed ID: 29328496
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Vasopressin for Septic Shock in Patients on Chronic Renin-Angiotensin-Aldosterone System Inhibitors.
Erwin BL; Denaburg MA; Barker AB; McArdle PJ; Windham ST; Morgan CJ
Crit Care Med; 2017 Dec; 45(12):e1226-e1232. PubMed ID: 28991825
[TBL] [Abstract][Full Text] [Related]
20. Vasopressin Plasma Concentrations Are Not Associated with Hemodynamic Response to Exogenous Vasopressin for Septic Shock.
Yerke JR; Sacha GL; Scheraga RG; Culver DA; Abraham S; Torbic H; Lam SW; Ammar MA; Olman MA; Bauer SR
Pharmacotherapy; 2020 Jan; 40(1):33-39. PubMed ID: 31705703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
